These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 502006)

  • 21. Proceedings: Fibrinogen/fibrin degradation products in defibrination syndrome analysed on the basis of molecular weight on gel exclusion chromatography.
    Kazama M; Abe T
    Thromb Diath Haemorrh; 1975 Sep; 34(1):339-40. PubMed ID: 1188772
    [No Abstract]   [Full Text] [Related]  

  • 22. [Methods of determination of fibrin fibrinogen degradation products (review of the literature)].
    Guseínov ChS; Prozorovskaia NN; Mikhaĭlova ND; Gorelova AM; Lagutina NIa
    Lab Delo; 1978; (5):259-66. PubMed ID: 79007
    [No Abstract]   [Full Text] [Related]  

  • 23. [Interaction of fibrinogen and fibrin with protamine sulfate].
    Mikhalovskaia LI; Varetskaia TV; Belitser VA
    Ukr Biokhim Zh (1978); 1988; 60(4):3-9. PubMed ID: 3188253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The investigation on early diagnosis of the bladder tumor. II: A study on urinary cytology, urinary fibrin/fibrinogen degradation products, tissue fibrin deposition and tissue plasminogen activator activity in patients with bladder tumors (author's transl)].
    Tanahashi T
    Nihon Hinyokika Gakkai Zasshi; 1980 Sep; 71(9):1047-54. PubMed ID: 7193258
    [No Abstract]   [Full Text] [Related]  

  • 25. Quantitative assessment of soluble fibrin in plasma by affinity chromatography--a comparative study with desAA-fibrin, desAABB-fibrin and fibrinogen.
    Thiel W; Delvos U; Müller-Berghaus G
    Thromb Haemost; 1985 Aug; 54(2):533-8. PubMed ID: 4082091
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of fibrinogen and fibrin degradation products in serum by staphylococcal clumping test.
    Hawiger J; Niewiarowski S; Gurewich V; Thomas DP
    J Lab Clin Med; 1970 Jan; 75(1):93-108. PubMed ID: 4243578
    [No Abstract]   [Full Text] [Related]  

  • 27. [An analysis of a disorder in the fibrin-forming phase in virtually healthy middle-aged and elderly subjects by using the ancistron test].
    Platonova TN; Sushko OO; Lukinova NI; Solovĭov DA
    Fiziol Zh (1994); 1994; 40(3-4):63-70. PubMed ID: 7621957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of anesthesia and surgery on serum and urinary fibrinogen/fibrin degradation products (FDP) levels in man (author's transl)].
    Shinozaki Y; Takiguchi M; Oyama T
    Masui; 1978 Mar; 27(3):253-9. PubMed ID: 650865
    [No Abstract]   [Full Text] [Related]  

  • 29. [The fibrinogen-fibrin-fibrinolysis system in rheumatoid arthritis].
    Belitskaia GA; Palienko IA; Shevchenko LI; Fedorova NE
    Vrach Delo; 1989 Jan; (1):47-50. PubMed ID: 2718445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. GPR-phoresis, a novel approach to determining fibrin monomer and other macromolecular derivatives of fibrinogen and fibrin in blood.
    Shainoff JR; Urbanic DA; DiBello PM; Valenzuela V
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):87-92. PubMed ID: 8457658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunohistochemical characterization of fibrin(ogen)-related antigens in human tissues using monoclonal antibodies.
    Bini A; Mesa-Tejada R; Fenoglio JJ; Kudryk B; Kaplan KL
    Lab Invest; 1989 Jun; 60(6):814-21. PubMed ID: 2659890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Estimation of the degradation products of fibrinogen and fibrin (DPF) in malignant gynecological tumours (author's transl)].
    Kudela M; Fisherová E; Krc I
    Cesk Gynekol; 1979 Jul; 44(6):413-6. PubMed ID: 498294
    [No Abstract]   [Full Text] [Related]  

  • 33. The stimulatory capacity of soluble fibrin prepared from high and low molecular weight fibrinogen on plasminogen activation.
    Halvorsen S; Skjønsberg OH; Godal HC
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):133-7. PubMed ID: 8457641
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Soluble fibrin complexes and fibrinogen heterogeneity in diabetes mellitus.
    Tsianos EB; Stathakis NE
    Thromb Haemost; 1980 Dec; 44(3):130-4. PubMed ID: 6162208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mechanism of self-assembly of soluble fibrin oligomers and the role of fibrinopeptides A and B in this process].
    Rozenfel'd MA; Gershkovich KB; Kuznetsov DV; Meshkov BB; Gontar' ID
    Mol Biol (Mosk); 1986; 20(4):1098-110. PubMed ID: 3762532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biological behavior of higher molecular weight products of fibrinolysis.
    Chang ML; Bang NU
    J Lab Clin Med; 1977 Jul; 90(1):216-26. PubMed ID: 874368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Functional changes of platelet and its preservation during and after extracorporeal circulation (author's transl)].
    Isomura K
    Nihon Kyobu Geka Gakkai Zasshi; 1979 Sep; 27(9):1235-49. PubMed ID: 501169
    [No Abstract]   [Full Text] [Related]  

  • 38. [Distinction between fibrinogen and fibrin degradation products in serum from patients with DIC (author's transl)].
    Yoshioka K; Yamamoto T; Yamauchi E; Mizuno S; Miyata H
    Rinsho Ketsueki; 1981 Sep; 22(9):1401-5. PubMed ID: 7334618
    [No Abstract]   [Full Text] [Related]  

  • 39. [Standarization of the staphylococcal clumping test (SCT) for the detection of fibrinogen/fibrin degradation products (FDP) in serum (author's transl)].
    Contreras P; Salazar R
    Rev Med Chil; 1975 Aug; 103(8):551-4. PubMed ID: 1197971
    [No Abstract]   [Full Text] [Related]  

  • 40. Characterisation of serum fibrinogen degradation products using gel chromatography and radioimmunoassay.
    Ratky SM; Sykes A; Cooke ED; Gordon YB
    Thromb Haemost; 1977 Jun; 37(3):471-6. PubMed ID: 578027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.